| Literature DB >> 34215851 |
Moon Hee Lee1,2,3, Riku Turkki4, Satu Mustjoki5,6,7,8, Anna Kreutzman9,10,11, Oscar Brück12,13,14,15, Ilona Uski1,2,3, Patrick Penttilä16, Lassi Paavolainen4, Panu Kovanen17, Petrus Järvinen16, Petri Bono18, Teijo Pellinen4.
Abstract
While the abundance and phenotype of tumor-infiltrating lymphocytes are linked with clinical survival, their spatial coordination and its clinical significance remain unclear. Here, we investigated the immune profile of intratumoral and peritumoral tissue of clear cell renal cell carcinoma patients (n = 64). We trained a cell classifier to detect lymphocytes from hematoxylin and eosin stained tissue slides. Using unsupervised classification, patients were further classified into immune cold, hot and excluded topographies reflecting lymphocyte abundance and localization. The immune topography distribution was further validated with The Cancer Genome Atlas digital image dataset. We showed association between PBRM1 mutation and immune cold topography, STAG1 mutation and immune hot topography and BAP1 mutation and immune excluded topography. With quantitative multiplex immunohistochemistry we analyzed the expression of 23 lymphocyte markers in intratumoral and peritumoral tissue regions. To study spatial interactions, we developed an algorithm quantifying the proportion of adjacent immune cell pairs and their immunophenotypes. Immune excluded tumors were associated with superior overall survival (HR 0.19, p = 0.02) and less extensive metastasis. Intratumoral T cells were characterized with pronounced expression of immunological activation and exhaustion markers such as granzyme B, PD1, and LAG3. Immune cell interaction occurred most frequently in the intratumoral region and correlated with CD45RO expression. Moreover, high proportion of peritumoral CD45RO+ T cells predicted poor overall survival. In summary, intratumoral and peritumoral tissue regions represent distinct immunospatial profiles and are associated with clinicopathologic characteristics.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34215851 PMCID: PMC8592837 DOI: 10.1038/s41379-021-00864-0
Source DB: PubMed Journal: Mod Pathol ISSN: 0893-3952 Impact factor: 7.842
Patient characteristics.
| Clinical variables | Patients |
|---|---|
| Age (years), median [range] | 64.9 [41.2–83.2] |
| Gender (male) | 37 (58%) |
| T | |
| 1 | 15 (23%) |
| 2 | 10 (16%) |
| 3 | 37 (58%) |
| 4 | 2 (3%) |
| N | |
| 0 | 47 (73%) |
| 1 | 17 (27%) |
| M | |
| 0 | 34 (53%) |
| 1 | 30 (47%) |
| Stage | |
| 1 | 8 (13%) |
| 2 | 9 (14%) |
| 3 | 16 (25%) |
| 4 | 31 (48%) |
| Fuhrman grade | |
| 1 | 4 (6%) |
| 2 | 24 (39%) |
| 3 | 29 (45%) |
| 4 | 6 (9%) |
| Mortality in 5 years | 36 (56%) |
| Sunitinib response (RECIST criteria) | |
| Partial response | 17 (27%) |
| Stable disease | 35 (55%) |
| Progressive disease | 6 (9%) |
| Not defined | 6 (9%) |
| Sunitinib treatment time (days), median [range] | 255 [13–2028] |
| Sunitinib dosage | |
| 25 mg | 17 (27%) |
| 37 mg | 31 (48%) |
| 50 mg | 16 (25%) |
| Sunitinib dose reduction | 31 (48%) |
| Sunitinib dose escalation | 22 (34%) |
| Progression-free survival events | |
| Treatment failure | 32 (43%) |
| Censored, end of follow-up | 13 (18%) |
| Censored, side effects | 18 (24%) |
| Censored, request by the patient | 1 (1%) |
| Treatment prior to sunitinib | |
| Targeted therapy | 0 (0%) |
| Interferon-α | 9 (14%) |
| MSKCC risk class | |
| Low | 14 (22%) |
| Intermediate | 43 (67%) |
| High | 7 (11%) |
Fig. 1Defining immune topographies.
A Overview of the study. Nephrectomy samples of renal cell carcinoma (RCC) patients were reconstructed into tissue microarrays (TMA) and stained with H&E and multiplex immunohistochemistry (mIHC). The intratumoral (IT), peritumoral (PT) and normal control tissue were examined separately. A cell classifier was developed to detect lymphocytes from H&E morphology. Cells were detected and classified in mIHC images based on marker intensity and co-localization. B Representative H&E images of different immune topographies (upper row) and corresponding cell detection and classification results (bottom row). Lymphocytes are red-colored and non-lymphocytes yellow-colored. C Two-phase clustering of (1) IT lymphocyte proportion and (2) the arithmetic difference of IT and PT lymphocyte proportion with Euclidean distance. D Linear regression of IT and PT lymphocyte proportions (plot) and Spearman correlation (left upper corner). E Kaplan–Meier visualization of overall survival from diagnosis by immune topographies. F Characterization of excluded immune topography by number of metastases and G MSKCC risk group with barplots and Fisher’s test. H Barplots of genetic alterations in most commonly mutated genes and tumors with an immune hot, immune excluded, and immune cold topography.
Fig. 2Characterization of immune contextures.
A Panel design used in multiplex immunohistochemistry (mIHC). GFP, Cy3, Cy5, and Cy7 represents fluorescence channels and Chromo1 and Chromo2 chromogenic channels. B Representative fluorescence and chromogen staining between intratumoral (IT) and peritumoral (PT) tissues. C Contexture-level heatmap of immunophenotypes in IT, PT, and control tissues with median-averaged immune cell proportions. Clustering has been computed with the Euclidean distance of immunophenotype correlations (Spearman). D Spearman correlation between IT and PT immunophenotypes. Significance: ***p < 0.001, **p < 0.01, *p < 0.05. E Patient-level heatmap of immunophenotypes in IT and control tissues. Clustering has been computed with the Euclidean distance of immunophenotype correlations. F Balloonplot visualizing the log10 fold-change difference of immunophenotype proportions between immune topographies. Each topography has been compared to the pooled group of other topographies. The balloon size corresponds to the p-value (Wilcoxon test). Only immunophenotypes differing in any comparison (p < 0.05) are shown.
Fig. 3Spatial immune cell network.
A Visualization of the Euclidean distance computed for each cell pair. B Visualization of the quantitative lymphocyte cellular (upper) and phenotypic (lower) network. Arrows in the cellular network represents individual computed comparisons, and in the phenotypic network the immunophenotypes compared between (non-)interacting immune cells. C Spearman correlation of interacting immune cell pairs between IT and PT regions. D Panel of comparisons of the cellular interaction frequency by intratumoral (IT), peritumoral (PT), and healthy (H) tissues. E Comparison of immunophenotypes by immune contexture (H, IT, PT) and interactive immune cell pair. Immunophenotypes are reported for the first immune cell by order. The fold-change (FC) has been calculated as the 10-fold logarithmic immunophenotype expression difference between interacting and non-interacting cells. For instance, “PT T-NK” represents immunophenotypes calculated for T cells interacting with NK cells in peritumoral renal tissue, and the red circle visualizes higher proportion of TIM3 expression in interacting vs. non-interacting T cells. F Digital staining for visualizing the location of TIM3+ T cells in PT and healthy renal tissue. IT tissues have been omitted for clarification. G Comparison of immunophenotypes by immune topography and interactive immune cell pair. The FC represents the 10-fold logarithmic immunophenotype expression difference between interacting and non-interacting cells. Immunophenotypes are reported for the first immune cell by order. H Digital staining for visualizing the location of CD45RO+ T cells and NK cells in immune hot and excluded renal tissues. I Spearman correlation matrix of intratumoral (IT) and peritumoral (PT) T-cell subsets. J Spearman correlation matrix between the proportion (rows) of IT and PT cytotoxic (Tc) and helper T cells (Th) and proportions of cell interactions (columns). The color scaling represents the correlation coefficient (red positive, blue negative). p-values have been adjusted with Benjamin & Hochberg correction. Only significant correlations (adjusted p-value < 0.05) are color-labeled. Significance: ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 4Association of immune cells and clinical variables.
A Association of clinical factors with IT and PT immunophenotypes (upper) and immunophenotypes based on interaction status (lower). Clinical factors have been categorized into two classes based on median. The color scale represents the log10 fold-change between each subgroup such as high vs. low patient age. Only immunophenotypes significant in any correlation (p < 0.05) are shown. B IT and PT immunophenotypes, immune cell interaction, and spatial immunophenotypes have been analyzed with Cox regression analysis (log-rank test) for overall survival. C Kaplan–Meier visualization of overall survival by IT and PT CD45RO+ cytotoxic T cells.